CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer

Journal of Clinical Oncology

Volumn 10, Issue 8, 1992, Pages 1225-1229

  Masuda, Noriyuki ^a   Fukuoka, Masahiro ^a   Kusunoki, Yoko ^a   Motsui, Kaoru ^a   Takifuji, Nobuhide ^a   Kudoh, Shinzoh ^a   Negoro, Shunichi ^a   Nishioka, Masayuki ^a   Nakagawa, Kazuhiko ^a   Takada, Minoru ^a  

^a OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IRINOTECAN; VINCRISTINE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DRUG RESISTANCE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG SMALL CELL CANCER; MALE; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CARCINOMA, SMALL CELL; DRUG EVALUATION; DRUG RESISTANCE; FEMALE; HUMAN; LUNG NEOPLASMS; MALE; MIDDLE AGE; PROSPECTIVE STUDIES; RECURRENCE; SUPPORT, NON-U.S. GOV'T; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0026680292     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1992.10.8.1225     Document Type: Article

References (36)

1. Morstyn G, Ihde DC, Lichter AS, et al: Small cell lung cancer 1973-1983: Early progress and recent obstacles. Int J Radiat Oncol Biol Phys 10:515-539, 1984
2. Smith IE, Sappiro AP, Bondy PK, et al: Long-term survival five years or more after combination chemotherapy and radiotherapy for small cell lung carcinoma. Eur J Cancer Clin Oncol 17:1249-1253, 1981
3. Livingston RB, Stephens RL, Bonnet JD, et al: Long-term survival and toxicity in small cell lung cancer. Am J Med 77:415-417, 1984
4. Johnson BE, Ihde DC, Bunn PA, et al: Patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. Data on potential cures, chronic toxicities, and late relapses after a five-to eleven-year follow-up. Ann Intern Med 103:430-438, 1985
5. Choi NC, Carey RW, Kaufman SD, et al: Small cell carcinoma of the lung. A progress report of 15 years' experience. Cancer 59:6-14, 1987
6. Niiranen A: Long-term survival in small cell lung carcinoma of the lung. Eur J Cancer Clin Oncol 24:749-752, 1988
7. Fukuoka M, Masuda N, Matsui K, et al: Combination chemotherapy with or without radiation therapy in small cell lung cancer. An analysis of a 5-year follow-up. Cancer 65:1678-1684, 1490
8. Niederle N, Schütte H: Chemotherapeutic results in small cell lung cancer, in Seeber S (ed): Small-Cell Lung Cancer, vol 97. Berlin, Germany, Springer-Verlag, 1985, pp 127-145
9. Wall ME, Wani MC, Cook CE, et al: Plant antitumor agents, I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 88:3888-3890, 1966
10. Hsiang YH, Hertzberg R, Hecht S, et al: Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260:14873-14878, 1985
11. Andoh T, Ishii K, Suzuki Y, et al: Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc Natl Acad Sci U S A 84:5565-5569, 1987
12. Li LH, Fraser TJ, Olin EJ, et al: Action of camptothecin on mammalian cells in culture. Cancer Res 32:2643-2650, 1972
13. Drewinko B, Freireich EJ, Gottlieb JA: Lethal activity of camptothecin sodium on human lymphoma cells. Cancer Res 34:747-750, 1974
14. Gallo RC, Whang-Peng J, Adamson RH: Studies on the antitumor activity mechanism of action, and cell cycle effects of camptothecin. J Natl Cancer Inst 46:789-795, 1971
15. Muggia FM, Creaven PJ, Hansen HH, et al: Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): Correlation with preclinical studies. Cancer Chemother Rep 56:515-521, 1972
16. Moertel CG, Schutt AJ, Reitemeier RJ, et al: Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Treat Rep 56:95-101, 1972
17. Gottlieb JA, Luce JK: Treatment of malignant melanoma with camptothecin (NSC-100880). Cancer Chemother Rep 56:103-105, 1972
18. Creaven PJ, Allen LM, Muggia FM: Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment: Relation to dose and toxicity. Cancer Chemother Rep 56:573-578, 1972
19. Kunimoto T, Nitta K, Tanaka T, et al: Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 47:5944-5947, 1987
20. Matsuzaki T, Yokokura T, Mutai M, et al: Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice. Cancer Chemother Pharmacol 21:308-312, 1988
21. Tsuruo T, Matsuzaki T, Matsushita M, et al: Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother Pharmacol 21:71-74, 1988
22. Taguchi T, Wakui A, Hasegawa K, et al: Phase I clinical study of CPT-11. Gan-To-Kagakuryoho 17:115-120, 1990 (in Japanese)
23. Ohno R, Okada K, Masaoka T, et al: An early phase II study of CPT-11: A new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol 8:1907-1912, 1990
24. Negoro S, Fukuoka M, Masuda N, et al: Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst 83:1164-1168, 1991
25. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48, Geneva, Switzerland, World Health Organization, 1979
26. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
27. Kawahara M, Furuse K, Fukuoka M, et al: Limited disease (LD) small cell lung cancer (SCLC) treated with concurrent cisplatin/etoposide (CP/VP) plus chest radiotherapy (RT). Proc Am Soc Clin Oncol 9:249, 1990 (abstr)
28. Masuda N, Fukuoka M, Negoro N, et al: CODE chemotherapy with or without recombinant human granulocyte colony-stimulating factor (rhG-CSF) in extensive-stage (ES) small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 10:254, 1991 (abstr)
29. Aisner J: Identification of new drugs in small cell lung cancer. Phase II agents first? Cancer Treat Rep 71:1131-1133, 1987
30. Cullen M: Evaluating new drugs in patients with chemosensitive tumours: Ethical dilemmas in extensive small cell lung cancer. Lung Cancer 5:1-7, 1989
31. Evans WK, Osoba D, Feld R, et al: Etoposide (VP-16) and cisplatin: An effective treatment for relapse in small cell lung cancer. J Clin Oncol 3:65-71, 1985
32. Lopez JA, Mann J, Grapski RT, et al: Etoposide and cisplatin salvage chemotherapy for small cell lung cancer. Cancer Treat Rep 69:369-371, 1985
33. Porter LL, Johnson DH, Hainsworth JD, et al: Cisplatin and etoposide combination chemotherapy for refractory small cell carcinoma of the lung. Cancer Treat Rep 69:479-481, 1985
34. Masuda N, Fukuoka M, Matsui K, et al: Evaluation of high-dose etoposide combined with cisplatin for treating relapsed small cell lung cancer. Cancer 65:2635-2640, 1990
35. Murray N, Shah A, Osoba D, et al: Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer. J Clin Oncol 9:1632-1638, 1991
36. Fukuoka M, Niitani H, Suzuki A, et al: A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 10:16-20, 1992